These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10959714)

  • 1. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.
    Herzog RW; Arruda VR; Fisher TH; Read MS; Nichols TC; High KA
    Thromb Haemost; 2000 Aug; 84(2):352-4. PubMed ID: 10959714
    [No Abstract]   [Full Text] [Related]  

  • 2. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine.
    Chao H; Walsh CE
    Thromb Haemost; 1999 Oct; 82(4):1378. PubMed ID: 10544943
    [No Abstract]   [Full Text] [Related]  

  • 3. Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
    Brooks MB; Gu W; Ray K
    J Am Vet Med Assoc; 1997 Dec; 211(11):1418-21. PubMed ID: 9394892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX.
    Chung KS; Goldsmith JC; Roberts HR
    Bibl Haematol; 1977; 44():68-74. PubMed ID: 617785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor IX antigen by radioimmunoassay in heterozygotes for hemophilia B.
    Thompson AR
    Thromb Res; 1977 Aug; 11(2):193-203. PubMed ID: 905971
    [No Abstract]   [Full Text] [Related]  

  • 6. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM; Sigman JL; Read MS; Stewart PF; McCarthy KP; Timony GA; Leppanen SD; Rup BJ; Keith JC; Garzone PD; Schaub RG
    Blood; 1996 Oct; 88(7):2603-10. PubMed ID: 8839853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The abnormal factor IX of hemophilia B+ variants.
    Bertina RM; Veltkamp JJ
    Thromb Haemost; 1978 Oct; 40(2):335-49. PubMed ID: 734633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
    Xu L; Mei M; Haskins ME; Nichols TC; O'donnell P; Cullen K; Dillow A; Bellinger D; Ponder KP
    Thromb Res; 2007; 120(2):269-80. PubMed ID: 17095052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A simple analytic method of the activation mechanism of factor IX using Western blotting].
    Sakai T; Ohkubo Y; Tanaka I; Yamamoto K; Yoshioka A; Fukui H
    Rinsho Ketsueki; 1987 Jan; 28(1):47-52. PubMed ID: 3573331
    [No Abstract]   [Full Text] [Related]  

  • 10. Antiserum against factor IX shortens the bovine thromboplastin coagulation time of human plasma.
    Orstavik KH; Laake K
    Thromb Res; 1978 Mar; 12(3):455-65. PubMed ID: 653636
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of EDTA in the electroimmunoassay of factor IX antigen in warfarin-treated patients.
    Yang HC
    Thromb Res; 1979; 15(1-2):89-94. PubMed ID: 113906
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunoradiometric assay of factor IX antigen using monoclonal antibody and classification of hemophilia B].
    Yoshioka A; Ohkubo Y; Nishino M; Sakai T; Sugimoto M; Nishimura T; Tanaka I; Fukui H
    Rinsho Ketsueki; 1985 Feb; 26(2):159-65. PubMed ID: 4021109
    [No Abstract]   [Full Text] [Related]  

  • 13. Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques.
    Ishiwata A; Mimuro J; Mizukami H; Kashiwakura Y; Yasumoto A; Sakata A; Ohmori T; Madoiwa S; Ono F; Shima M; Yoshioka A; Ozawa K; Sakata Y
    Thromb Res; 2010 Jun; 125(6):533-7. PubMed ID: 20170943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of an occult inhibitor to factor IX in a haemophilia B patient.
    Miller CH; Orstavik KH; Hilgartner MW
    Br J Haematol; 1985 Oct; 61(2):329-38. PubMed ID: 4041376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on immunological assay of vitamin-K dependent factors. III. A double monoclonal immunoradiometric assay for factor IX antigen.
    Mikami S; O'Brien DP; Mellars G; Goodall AH; Tuddenham EG
    Br J Haematol; 1986 Mar; 62(3):513-24. PubMed ID: 3485443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B.
    Tomokiyo K; Teshima K; Nakatomi Y; Watanabe T; Mizuguchi J; Nozaki C; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Thromb Res; 2001 May; 102(4):363-74. PubMed ID: 11369429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody.
    Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG
    Blood; 1982 Mar; 59(3):664-70. PubMed ID: 7059674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model.
    French RA; Samelson-Jones BJ; Niemeyer GP; Lothrop CD; Merricks EP; Nichols TC; Arruda VR
    Blood Adv; 2018 Mar; 2(5):505-508. PubMed ID: 29500218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
    Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
    Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
    Noyes CM; Griffith MJ; Roberts HR; Lundblad RL
    Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4200-2. PubMed ID: 6603618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.